deltatrials
Terminated PHASE1 NCT01829971

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Sponsor: Cancer Prevention Research Institute of Texas

Conditions Lymphoma Melanoma Multiple Myeloma NSCLC Primary Liver Cancer Renal Cell Carcinoma SCLC
Interventions MRX34
Updated 7 times since 2017 Last updated: Sep 26, 2016 Started: Apr 30, 2013 Primary completion: Mar 31, 2017 Completion: May 31, 2017

A PHASE1 clinical study on Lymphoma and Melanoma, this trial is terminated or withdrawn. The trial is conducted by Cancer Prevention Research Institute of Texas and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Prevention Research Institute of Texas
  • Mirna Therapeutics, Inc.
Data source: Mirna Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dallas, United States
  • • Houston, United States
  • • San Antonio, United States
  • • Scottsdale, United States
  • • Seoul, South Korea